NCT04323956 2026-02-02Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell LymphomaMayo ClinicPhase 1 Active not recruiting50 enrolled
NCT04509700 2025-12-10Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Incyte CorporationPhase 2 Active not recruiting112 enrolled